

Pulmonary Hypertension Part II References

Special Guest: Zach Smith, PharmD, BCPS, BCCCP, FCCP

Guidelines

Klinger JR, Elliott CG, Levine DJ, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. *Chest*. 2019 Mar;155(3):565-586. <https://pubmed.ncbi.nlm.nih.gov/30660783/>

ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J*. 2022 Oct 11;43(38):3618-3731. <https://pubmed.ncbi.nlm.nih.gov/36017548/>

Harjola VP, Mebazaa A, Čelutkienė J, et al. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. *Eur J Heart Fail*. 2016 Mar;18(3):226-41. <https://pubmed.ncbi.nlm.nih.gov/26995592/>

Review Articles

Abraham T, Wu G, Vastey F, et al. Role of combination therapy in the treatment of pulmonary arterial hypertension. *Pharmacotherapy*. 2010 Apr;30(4):390-404. <https://pubmed.ncbi.nlm.nih.gov/20334459/>

Maron BA. Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer. *J Am Heart Assoc*. 2023 Apr 18;12(8):e029024. <https://pubmed.ncbi.nlm.nih.gov/37026538/>

Caputo A, Papa S, Manzi G, et al. Medical Management of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension. *Curr Heart Fail Rep*. 2023 Aug;20(4):263-270. <https://pubmed.ncbi.nlm.nih.gov/37486563/>

Bishop BM, Mauro VF, Khouri SJ. Practical considerations for the pharmacotherapy of pulmonary arterial hypertension. *Pharmacotherapy*. 2012 Sep;32(9):838-55. <https://pubmed.ncbi.nlm.nih.gov/22806762/>

Jentzer JC, Mathier MA. Pulmonary Hypertension in the Intensive Care Unit. *J Intensive Care Med*. 2016 Jul;31(6):369-85. <https://pubmed.ncbi.nlm.nih.gov/25944777/>

Articles Referenced

Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. *N Engl J Med*. 1996 Feb 1;334(5):296-301. <https://pubmed.ncbi.nlm.nih.gov/8532025/>

AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. *N Engl J Med*. 2015 Aug 27;373(9):834-44. <https://pubmed.ncbi.nlm.nih.gov/26308684/>

CHEST-1 Study Group. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. *N Engl J Med*. 2013 Jul 25;369(4):319-29. <https://pubmed.ncbi.nlm.nih.gov/23883377/>

Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. *N Engl J Med*. 1992 Jul 9;327(2):76-81. <https://pubmed.ncbi.nlm.nih.gov/1603139/>